Cellebrite DI (CLBT) Stock Forecast, Price Target & Predictions
CLBT Stock Forecast
Cellebrite DI stock forecast is as follows: an average price target of $16.67 (represents a 2.02% upside from CLBT’s last price of $16.34) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
CLBT Price Target
The average price target for Cellebrite DI (CLBT) is $16.67 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $16.00. This represents a potential 2.02% upside from CLBT's last price of $16.34.
CLBT Analyst Ratings
According to 7 Wall Street analysts, Cellebrite DI's rating consensus is 'Buy'. The analyst rating breakdown for CLBT stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cellebrite DI Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | Eric Martinuzzi | Loop Capital Markets | $17.00 | $16.14 | 5.30% | 4.04% |
| Aug 16, 2024 | Tomer Zilberman | Bank of America Securities | $17.00 | $14.96 | 13.64% | 4.04% |
| Apr 01, 2024 | Jeff Van Rhee | Craig-Hallum | $16.00 | $11.08 | 44.40% | -2.08% |
The latest Cellebrite DI stock forecast, released on Aug 16, 2024 by Eric Martinuzzi from Loop Capital Markets, set a price target of $17.00, which represents a 5.30% increase from the stock price at the time of the forecast ($16.14), and a 4.04% increase from CLBT last price ($16.34).
Cellebrite DI Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $17.00 | $17.00 | $16.67 |
| Last Closing Price | $16.34 | $16.34 | $16.34 |
| Upside/Downside | 4.04% | 4.04% | 2.02% |
In the current month, the average price target of Cellebrite DI stock is $17.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 4.04% increase as opposed to Cellebrite DI's last price of $16.34. This month's average price target is down 0.00% compared to last quarter, and up 1.98% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | Lake Street | Buy | Buy | Hold |
| Aug 16, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Aug 16, 2024 | Deutsche Bank | Buy | Buy | Hold |
| May 24, 2024 | Lake Street | Buy | Buy | Hold |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 19, 2024 | Lake Street | - | Buy | Initialise |
| Apr 01, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Apr 01, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Mar 13, 2024 | William Blair | - | Outperform | Upgrade |
| Feb 16, 2024 | Bank of America Securities | - | Buy | Upgrade |
Cellebrite DI's last stock rating was published by Lake Street on Aug 16, 2024. The company gave CLBT a "Buy" rating, the same as its previous rate.
Cellebrite DI Financial Forecast
Cellebrite DI Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $71.23M | $74.02M | $71.67M | $62.57M | $62.38M | $67.91M | $65.89M |
| Avg Forecast | $150.04M | $139.69M | $131.51M | $127.01M | $126.01M | $118.56M | $111.64M | $105.64M | $106.98M | $102.06M | $91.94M | $85.34M | $85.56M | $82.13M | $72.52M | $69.44M | $74.53M | $72.13M | $69.14M | $62.58M | $63.99M | $59.25M |
| High Forecast | $151.42M | $140.97M | $132.72M | $128.18M | $127.17M | $119.65M | $112.67M | $106.61M | $107.96M | $102.52M | $92.79M | $86.12M | $88.14M | $84.33M | $73.19M | $70.08M | $75.22M | $72.80M | $69.61M | $63.01M | $64.42M | $59.66M |
| Low Forecast | $147.01M | $136.87M | $128.85M | $124.45M | $123.47M | $116.17M | $109.38M | $103.50M | $104.82M | $101.33M | $90.09M | $83.61M | $82.44M | $80.50M | $71.06M | $68.04M | $73.03M | $70.68M | $68.19M | $61.72M | $63.11M | $58.44M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.99% | 0.99% | 0.91% | 1.00% | 1.06% | 1.11% |
Cellebrite DI's average Quarter revenue forecast for Jun 23 based on 3 analysts is $72.52M, with a low forecast of $71.06M, and a high forecast of $73.19M. CLBT's average Quarter revenue forecast represents a 1.81% increase compared to the company's last Quarter revenue of $71.23M (Mar 23).
Cellebrite DI EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.58M | $12.19M | $1.22M | $-3.34M | $166.00K | $105.85M | $34.63M |
| Avg Forecast | $10.55M | $9.82M | $9.25M | $8.93M | $8.86M | $8.34M | $7.85M | $7.43M | $7.52M | $7.18M | $6.47M | $6.00M | $6.02M | $5.78M | $5.10M | $4.88M | $5.24M | $5.07M | $4.86M | $4.40M | $4.50M | $4.17M |
| High Forecast | $10.65M | $9.91M | $9.33M | $9.02M | $8.94M | $8.41M | $7.92M | $7.50M | $7.59M | $7.21M | $6.53M | $6.06M | $6.20M | $5.93M | $5.15M | $4.93M | $5.29M | $5.12M | $4.90M | $4.43M | $4.53M | $4.20M |
| Low Forecast | $10.34M | $9.63M | $9.06M | $8.75M | $8.68M | $8.17M | $7.69M | $7.28M | $7.37M | $7.13M | $6.34M | $5.88M | $5.80M | $5.66M | $5.00M | $4.79M | $5.14M | $4.97M | $4.80M | $4.34M | $4.44M | $4.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.53% | 2.33% | 0.24% | -0.69% | 0.04% | 23.52% | 8.31% |
3 analysts predict CLBT's average Quarter EBITDA for Jun 23 to be $5.10M, with a high of $5.15M and a low of $5.00M. This is 97.46% upper than Cellebrite DI's previous annual EBITDA (Mar 23) of $2.58M.
Cellebrite DI Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-40.60M | $7.08M | $25.09M | $33.20M | $55.44M | $51.87M | $8.14M |
| Avg Forecast | $22.37M | $23.23M | $19.16M | $14.33M | $18.17M | $16.42M | $12.34M | $10.37M | $14.42M | $15.18M | $7.22M | $4.81M | $6.37M | $5.09M | $3.03M | $1.58M | $10.44M | $994.75K | $2.70M | $2.49M | $3.48M | $1.33M |
| High Forecast | $22.64M | $23.51M | $19.39M | $14.50M | $18.39M | $16.62M | $12.49M | $10.50M | $14.59M | $16.56M | $7.31M | $4.87M | $6.44M | $5.15M | $3.06M | $1.59M | $10.57M | $1.01M | $2.72M | $2.51M | $3.51M | $1.34M |
| Low Forecast | $21.78M | $22.62M | $18.66M | $13.95M | $17.70M | $15.99M | $12.02M | $10.10M | $14.04M | $13.80M | $7.03M | $4.69M | $5.31M | $4.07M | $2.95M | $1.53M | $10.17M | $968.64K | $2.65M | $2.44M | $3.42M | $1.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.77% | 0.68% | 25.22% | 12.30% | 22.29% | 14.90% | 6.14% |
Cellebrite DI's average Quarter net income forecast for Mar 23 is $1.58M, with a range of $1.53M to $1.59M. CLBT's average Quarter net income forecast represents a -77.74% decrease compared to the company's last Quarter net income of $7.08M (Dec 22).
Cellebrite DI SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $37.56M | $32.48M | $36.59M | $35.40M | $33.77M | $29.80M | $40.60M |
| Avg Forecast | $74.50M | $69.36M | $65.30M | $63.07M | $62.57M | $58.87M | $55.43M | $52.45M | $53.12M | $50.68M | $45.66M | $42.37M | $42.49M | $40.78M | $36.01M | $34.48M | $37.01M | $35.82M | $34.33M | $31.07M | $31.77M | $29.42M |
| High Forecast | $75.19M | $70.00M | $65.90M | $63.65M | $63.15M | $59.41M | $55.94M | $52.94M | $53.61M | $50.91M | $46.08M | $42.76M | $43.77M | $41.87M | $36.34M | $34.80M | $37.35M | $36.15M | $34.56M | $31.29M | $31.99M | $29.62M |
| Low Forecast | $73.00M | $67.96M | $63.98M | $61.80M | $61.31M | $57.68M | $54.31M | $51.39M | $52.05M | $50.31M | $44.73M | $41.52M | $40.94M | $39.97M | $35.28M | $33.79M | $36.26M | $35.10M | $33.86M | $30.65M | $31.34M | $29.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.88% | 1.02% | 1.03% | 1.09% | 0.94% | 1.38% |
Cellebrite DI's average Quarter SG&A projection for Jun 23 is $36.01M, based on 3 Wall Street analysts, with a range of $35.28M to $36.34M. The forecast indicates a -4.13% fall compared to CLBT last annual SG&A of $37.56M (Mar 23).
Cellebrite DI EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.22 | $0.04 | $0.13 | $0.18 | $0.29 | $0.29 | $0.06 |
| Avg Forecast | $0.11 | $0.12 | $0.10 | $0.07 | $0.09 | $0.08 | $0.06 | $0.05 | $0.07 | $0.08 | $0.04 | $0.02 | $0.03 | $0.03 | $0.02 | $0.01 | $0.05 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 |
| High Forecast | $0.11 | $0.12 | $0.10 | $0.07 | $0.09 | $0.08 | $0.06 | $0.05 | $0.07 | $0.08 | $0.04 | $0.02 | $0.03 | $0.03 | $0.02 | $0.01 | $0.05 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 |
| Low Forecast | $0.11 | $0.11 | $0.09 | $0.07 | $0.09 | $0.08 | $0.06 | $0.05 | $0.07 | $0.07 | $0.04 | $0.02 | $0.03 | $0.02 | $0.01 | $0.01 | $0.05 | - | $0.01 | $0.01 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.78% | 0.76% | 26.00% | 13.27% | 23.20% | 16.57% | 9.00% |
According to 3 Wall Street analysts, Cellebrite DI's projected average Quarter EPS for Mar 23 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -80.20% decrease compared to CLBT previous annual EPS of $0.04 (Dec 22).
Cellebrite DI Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STER | Sterling Check | $15.96 | $26.00 | 62.91% | Buy |
| EVCM | EverCommerce | $10.13 | $12.29 | 21.32% | Buy |
| CSGS | CSG Systems | $46.67 | $52.00 | 11.42% | Buy |
| CCSI | Consensus Cloud Solutions | $22.70 | $25.00 | 10.13% | Buy |
| SCWX | SecureWorks | $8.28 | $9.00 | 8.70% | Hold |
| CLBT | Cellebrite DI | $16.34 | $16.67 | 2.02% | Buy |
| EVTC | EVERTEC | $31.65 | $28.00 | -11.53% | Sell |
CLBT Forecast FAQ
Is Cellebrite DI a good buy?
Yes, according to 7 Wall Street analysts, Cellebrite DI (CLBT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of CLBT's total ratings.
What is CLBT's price target?
Cellebrite DI (CLBT) average price target is $16.67 with a range of $16 to $17, implying a 2.02% from its last price of $16.34. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cellebrite DI stock go up soon?
According to Wall Street analysts' prediction for CLBT stock, the company can go up by 2.02% (from the last price of $16.34 to the average price target of $16.67), up by 4.04% based on the highest stock price target, and down by -2.08% based on the lowest stock price target.
Can Cellebrite DI stock reach $20?
CLBT's average twelve months analyst stock price target of $16.67 does not support the claim that Cellebrite DI can reach $20 in the near future.
What is Cellebrite DI's current price target trend?
2 Wall Street analysts forecast a $17 price target for Cellebrite DI (CLBT) this month, up 4.04% from its last price of $16.34. Compared to the last 3 and 12 months, the average price target increased by 4.04% and increased by 2.02%, respectively.
What are Cellebrite DI's analysts' financial forecasts?
Cellebrite DI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $461.85M (high $466.1M, low $452.53M), average EBITDA is $32.48M (high $32.78M, low $31.83M), average net income is $57.31M (high $58M, low $55.81M), average SG&A $229.33M (high $231.44M, low $224.7M), and average EPS is $0.288 (high $0.292, low $0.281). CLBT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $548.25M (high $553.3M, low $537.18M), average EBITDA is $38.56M (high $38.91M, low $37.78M), average net income is $79.09M (high $80.03M, low $77.01M), average SG&A $272.23M (high $274.74M, low $266.74M), and average EPS is $0.398 (high $0.402, low $0.387).
Did the CLBT's actual financial results beat the analysts' financial forecasts?
Based on Cellebrite DI's last annual report (Dec 2022), the company's revenue was $270.65M, which missed the average analysts forecast of $278.38M by -2.78%. Apple's EBITDA was $10.24M, missing the average prediction of $19.58M by -47.71%. The company's net income was $120.8M, beating the average estimation of $16.62M by 626.65%. Apple's SG&A was $138.24M, beating the average forecast of $138.23M by 0.01%. Lastly, the company's EPS was $0.84, beating the average prediction of $0.0836 by 905.23%. In terms of the last quarterly report (Mar 2023), Cellebrite DI's revenue was $71.23M, beating the average analysts' forecast of $69.44M by 2.58%. The company's EBITDA was $2.58M, missing the average prediction of $4.88M by -47.11%. Cellebrite DI's net income was $-40.605M, missing the average estimation of $1.58M by -2676.98%. The company's SG&A was $37.56M, beating the average forecast of $34.48M by 8.93%. Lastly, the company's EPS was $-0.22, missing the average prediction of $0.00792 by -2877.78%